AI assistant
Sending…
SUPERNUS PHARMACEUTICALS, INC. — Director's Dealing 2025
Feb 24, 2025
31512_dirs_2025-02-24_844f9fc0-153e-4a41-a284-1a2d06cef60f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK: 0001356576
Period of Report: 2025-02-22
Reporting Person: Barlow Carrolee (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-22 | Common Stock | A | 5369 | — | Acquired | 22570 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-22 | Restricted Stock Units | $ | D | 5369 | Disposed | Common Stock (5369) | Direct |
Footnotes
F1: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F2: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025.
More from SUPERNUS PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 20
Regulatory Filings
2026
Apr 22
Regulatory Filings
2026
Apr 7
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Annual Report
2026
Mar 2
Director's Dealing
2026
Feb 26